Investorideas.com

Call 800 665 0411 to learn about our services

Search   Follow Investorideas on Twitter   Investorideas is on Facebook   Investorideas is on Youtube   Investorideas is on Pinterest  Investorideas is on stocktwits   Investorideas is on tumblr   Investorideas is on LinkedIn   Investorideas Instagram   Investorideas Telegram   Investorideas Gettr   Investorideas RSS


 


BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology, telemedicine, Covid-19

Like Biotech Stocks? View our Biotech Stocks Directory    Get News Alerts on Biotech Stocks


Featured Biotech stocks - Feature Your Company & Product Here

Biotech News

Biopharma Gains Another Shot on Goal With IND Approval
January 27, 2023 (Investorideas.com Newswire) The firm's CD19- and CD3-targeting monoclonal antibody is now cleared for evaluation in a Phase I clinical trial

Med Tech Co. Well-Poised for Revenue Growth This Year
January 26, 2023 (Investorideas.com Newswire) New revenue sources already in place are expected to boost cash flow 72% over the next 12 months, noted an H.C. Wainwright & Co. report.

Biotech's Novel Thin Formulation Improves Veteran-Aiding Treatment
January 25, 2023 (Investorideas.com Newswire) Awakn Life Sciences announced further details regarding its August 2022 announcement that it had "signed a twelve-month option agreement with a leading drug development, manufacturing, and delivery systems company to in-license a proprietary formulation and route of administration for ketamine."

Biopharma Creating COVID Drug Gets US$8.2M From the DOD
January 25, 2023 (Investorideas.com Newswire) This tranche, other cash and cash equivalents, and current cash flow are sufficient to get the developer of immunotherapeutics through 2023

Exploring Why The Economist Named this Biotech 'One To watch' in 2023
January 24, 2023 (Investorideas.com Newswire) As more researchers delve into the medicinal potentials of once-verboten compounds, forward-thinking companies like Awakn Life Sciences Corp. are leading the charge to map their most useful aspects and open access for people who need help now.

Telehealth Co. Expects More Growth in 2023
January 23, 2023 (Investorideas.com Newswire) Officials at telemedicine company Reliq Health Technologies say they expect to accelerate growth "significantly" in 2023

Berg Insight says 56.8 million patients worldwide are remotely monitored
Gothenburg, Sweden - January 19, 2023 (Investorideas.com Newswire) Berg Insight, the world's leading IoT market research provider, today released new findings on the mHealth market.

Biotech Stock News: American CryoStem (OTC Pink: CRYO) Announces FDA Approval of IND to Commence Phase I Clinical Trial for Long COVID/Post-Acute Sequelae of SARS-CoV-2 (PASC)
Eatontown, New Jersey - January 6, 2023 (Newsfile Corp.) (Investorideas.com Newswire) American CryoStem Corporation (OTC Pink: CRYO), a clinical-stage therapeutics company with a proprietary end-to-end core biotechnology platform of tissue-based cellular technologies that powers its clinical pipeline, announced today that it has received U.S. Food and Drug Administration (FDA) approval to proceed with a Phase I Clinical Trial for the treatment of Long COVID/PASC.

Biotech Stock News: Marvel Biosciences (TSXV: MRVL) Completes a Critical Manufacturing Milestone Required to Enter Phase 1 Human Trials Targeting Alzheimer's Disease and Depression
Calgary, Alberta - January 6, 2023 (Newsfile Corp.) (Investorideas.com Newswire) Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc., are pleased to announce that it has successfully completed a multi-kilogram scale run under current good manufacturing practices of the active pharmaceutical ingredient of the Company's lead asset MB-204 in partnership with Zhejiang Ausun Pharmaceutical Co., Ltd.

Biopharma Co.'s Burn Tissue Removal Product Approved
January 5, 2023 (Investorideas.com Newswire) Because of the green light from the U.S. Food and Drug Administration, H.C. Wainwright & Co. raised its target price on the developer of this drug

Subscribe to Biotech News RSS

Submit Articles   Search More Articles

Biotech Stock ETF's

First Trust NYSE Arca Biotech ETF ( NYSEArca: FBT ) The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.

iShares US Healthcare ( NYSEArca: IYH ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Health Care Index (the "underlying index"), which measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.

iShares US Healthcare Providers ( NYSEArca: IHF ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare providers sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Health Care Providers Index (the "underlying index"), which measures the performance of the healthcare providers sector of the U.S. equity market. The fund is non-diversified.

iShares US Medical Devices ( NYSEArca: IHI ) The investment seeks to track the investment results of an index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index (the "underlying index"), which measures the performance of the medical equipment sector of the U.S. equity market. The underlying index includes medical equipment companies such as manufacturers and distributors of medical devices such as magnetic resonance imaging (MRI) scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.

iShares Nasdaq Biotechnology ( NasdaqGIDS IBB ) The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.

Market Vectors Biotech ETF ( NYSE MKT:BBH ) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

PowerShares Dynamic Biotech & Genome ETF ( NYSEArca: PBE ) The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Other Ideas - Guest Posts and / or sponsored financial content

Learn how to be published on our site: Buy a guest post on Investorideas.com

Biotech News from Newsfile

Universal PropTech Announces Results of Voting at Shareholder Meeting
Toronto, Ontario--(Newsfile Corp. - January 27, 2023) - Universal PropTech Inc. (TSXV: UPI) ("UPI" or the "Company") is pleased to announce the results of matters voted on at its Special Meeting of Shareholders held earlier today. Details of the matters put forth are set out in the notice of meeting and management information circular dated December 19, 2022.Both the Transaction Resolution and the NEX Resolution, as more fully described in the Information Circular, were...

Irwin Naturals Signs Letter of Intent to Acquire Braxia Scientific
Strategic transaction assembles an experienced management and scientific team world-renowned in mental health treatment, research and developmentEstablishes large footprint of 17 specialized mental health clinics across North America, enhanced by a telehealth platform expected to extend access to critical treatments for millions of people across multiple states in the USCombined network of clinics creates a leading international mental health research platform for in-human clinical development of novel therapeuticsToronto, Ontario--(Newsfile Corp. - January 27, 2023) -...

Skye Bioscience Obtains Central IRB Approval for Phase 2 Clinical Trial with SBI-100 Ophthalmic Emulsion
San Diego, California--(Newsfile Corp. - January 27, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, reported that its Phase 2 clinical trial protocol has received study level approval from a central institutional review board ("IRB"). The Phase 2 study is a planned evaluation of SBI-100 Ophthalmic Emulsion ("OE") in patients with primary open angle glaucoma or ocular hypertension. SBI-100 OE...

Sona Nanotech to Acquire Cancer Therapy Developer Siva Therapeutics
This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated April 9, 2021 to its short form base prospectus dated March 31, 2021.Halifax, Nova Scotia--(Newsfile Corp. - January 26, 2023) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that it has entered into a binding agreement (the "Definitive Agreement") on January 26, 2023 to acquire Siva Therapeutics, Inc. ("Siva"), the...

Hemostemix' "Your Fountain of Youth" Trademark Granted by Japan Patent Office
Calgary, Alberta--(Newsfile Corp. - January 26, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the Japan Patent Office issued Kwalata Trading Limited, a wholly owned subsidiary of Hemostemix Inc., a trademark registration certificate for Your Fountain of Youth. "Your Fountain of Youth explains the benefit of leveraging your synergetic cell population as ACP-01 and it explains Hemostemix' business model," stated Thomas Smeenk, CEO....

Subscribe to Biotech News